Company news

Sutro Biopharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Sutro Biopharma Announces Proposed Public Offering

May 10, 2020

Sutro Biopharma Announces Pricing of $85.3 Million Public Offering

May 10, 2020

Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer

April 26, 2020

Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate

April 19, 2020

Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments

March 15, 2020

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck

March 11, 2020

Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development

February 4, 2020

Sutro Biopharma Appoints James Panek to Board of Directors

January 7, 2020

Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments

November 7, 2019

Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

October 15, 2019

Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

October 7, 2019

Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments

August 13, 2019

Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments

March 31, 2019

← Newer news releases

Decks

The 5 newest of 54 decks. Every deck is listed under its year.